{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:24:06Z","timestamp":1791289446397,"version":"4.3.0"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.phrs.2025.107690","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T07:36:32Z","timestamp":1741592192000},"page":"107690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["IUPHAR review \u2013 Novel therapeutic targets for schizophrenia treatment: A translational perspective"],"prefix":"10.1016","volume":"214","author":[{"given":"Veronica","family":"Begni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Marchesin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-5060","authenticated-orcid":false,"given":"Marco Andrea","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107690_bib1","author":"AbbVie","year":"2024","journal-title":"AbbVie Provid. Update Phase 2 Results Emraclidine Schizophr."},{"issue":"12","key":"10.1016\/j.phrs.2025.107690_bib2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.biopsych.2008.12.007","article-title":"Baseline and amphetamine-stimulated dopamine activity are related in drug-na\u00efve schizophrenic subjects","volume":"65","author":"Abi-Dargham","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107690_bib3","series-title":"Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia","author":"Acadia Pharmaceuticals Inc","year":"2024"},{"key":"10.1016\/j.phrs.2025.107690_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110449","article-title":"Clozapine reduces chemokine-mediated migration of lymphocytes by targeting NF-\u03baB and AKT phosphorylation","volume":"99","author":"Al Abadey","year":"2022","journal-title":"Cell. Signal."},{"issue":"8","key":"10.1016\/j.phrs.2025.107690_bib5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/ijnp\/pyad035","article-title":"Phase 2 results indicate evenamide, a selective modulator of glutamate release, is associated with clinically important long-term efficacy when added to an antipsychotic in patients with treatment-resistant schizophrenia","volume":"26","author":"Anand","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"02","key":"10.1016\/j.phrs.2025.107690_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/a-0960-9846","article-title":"Hippocampal dysfunction in schizophrenia and aberrant hippocampal synaptic plasticity in rodent model psychosis: a selective review","volume":"56","author":"Bartsch","year":"2023","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2025.107690_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euroneuro.2022.06.005","article-title":"Exposure to chronic stress impairs the ability to cope with an acute challenge: modulation by lurasidone treatment","volume":"61","author":"Begni","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2025.107690_bib8","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.3390\/ijms22084119","article-title":"Towards novel treatments for schizophrenia: molecular and behavioural signatures of the psychotropic agent SEP-363856","volume":"22","author":"Begni","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107690_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbi.2024.10.001","article-title":"Chronic treatment with the antipsychotic lurasidone modulates the neuroinflammatory changes associated with the vulnerability to chronic mild stress exposure in female rats","volume":"123","author":"Begni","year":"2025","journal-title":"Brain, Behav. Immun."},{"key":"10.1016\/j.phrs.2025.107690_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jpsychires.2022.12.003","article-title":"Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: two open-label pilot studies on treatment-resistant patients","volume":"158","author":"Bejerot","year":"2023","journal-title":"J. Psychiatr. Res."},{"issue":"8","key":"10.1016\/j.phrs.2025.107690_bib11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1177\/0271678X241238820","article-title":"PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [ 11C]MK-6884: quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator","volume":"44","author":"Belov","year":"2024","journal-title":"J. Cereb. Blood Flow. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2025.107690_bib12","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s41593-022-01182-7","article-title":"Analysis of the caudate nucleus transcriptome in individuals with schizophrenia highlights effects of antipsychotics and new risk genes","volume":"25","author":"Benjamin","year":"2022","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2025.107690_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.euroneuro.2012.04.015","article-title":"Striatal dopamine D2\/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis","volume":"23","author":"Bloemen","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2025.107690_bib14","author":"Boehringer Ingelheim Limited","year":"2025","journal-title":"Boehringer Provid. Update iclepertin Phase III Program Schizophr."},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12974-017-0962-y","article-title":"Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder","volume":"14","author":"Boerrigter","year":"2017","journal-title":"J. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.phrs.2025.107690_bib16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2025.107690_bib17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.tins.2024.08.011","article-title":"Rethinking the role of TRKB in the action of antidepressants and psychedelics","volume":"47","author":"Brunello","year":"2024","journal-title":"Trends Neurosci."},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgac006","article-title":"ENHANCE: phase 3, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin for schizophrenia in patients with an inadequate response to antipsychotic treatment","volume":"3","author":"Bugarski-Kirola","year":"2022","journal-title":"Schizophr. Bull. Open"},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","article-title":"Bitopertin in negative symptoms of schizophrenia\u2014results from the phase iii flashlyte and daylyte studies","volume":"82","author":"Bugarski-Kirola","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib20","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.1038\/s41467-023-41199-5","article-title":"Xanomeline displays concomitant orthosteric and allosteric binding modes at the M4 mAChR","volume":"14","author":"Burger","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.phrs.2025.107690_bib21","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.neuron.2014.07.028","article-title":"Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia","volume":"83","author":"Cabungcal","year":"2014","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.phrs.2025.107690_bib22","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1038\/npp.2014.4","article-title":"Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates","volume":"39","author":"Castner","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.phrs.2025.107690_bib23","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/0269881112444941","article-title":"Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment","volume":"26","author":"Chaudhry","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107690_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2025.107690_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamapsychiatry.2019.3377","article-title":"Ranking antipsychotics for efficacy and safety in schizophrenia","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41537-021-00190-z","article-title":"Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study","volume":"7","author":"Correll","year":"2021","journal-title":"Npj Schizophr."},{"key":"10.1016\/j.phrs.2025.107690_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173635","article-title":"Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist","volume":"890","author":"Cosi","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107690_bib28","first-page":"1","article-title":"What is the neurobiology of schizophrenia?","author":"Cummings","year":"2024","journal-title":"CNS Spectr."},{"issue":"03","key":"10.1016\/j.phrs.2025.107690_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/a-2228-6118","article-title":"Cannabidiol and its Potential Evidence-Based Psychiatric Benefits \u2013 A Critical Review","volume":"57","author":"Dammann","year":"2024","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2025.107690_bib30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archpsyc.65.4.378","article-title":"Dysfunctional neural plasticity in patients with schizophrenia","volume":"65","author":"Daskalakis","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.phrs.2025.107690_bib31","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","article-title":"Efficacy and safety of MIN-101: A 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia","volume":"174","author":"Davidson","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2025.107690_bib32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/sbac013","article-title":"Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia","volume":"48","author":"Davidson","year":"2022","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.phrs.2025.107690_bib33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14737175.2016.1174577","article-title":"ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes","volume":"16","author":"Davis","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.phrs.2025.107690_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106078","article-title":"Present and future antipsychotic drugs: a systematic review of the putative mechanisms of action for efficacy and a critical appraisal under a translational perspective","volume":"176","author":"de Bartolomeis","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107690_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108236","article-title":"Clozapine\u2019s multiple cellular mechanisms: what do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia","volume":"236","author":"de Bartolomeis","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2025.107690_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107510","article-title":"IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia","volume":"210","author":"Dean","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.119.260281","article-title":"SEP-363856, a novel psychotropic agent with a unique, non-D 2 receptor mechanism of action","volume":"371","author":"Dedic","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2025.107690_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175306","article-title":"Pro-cognitive effects of the GlyT1 inhibitor Bitopertin in rodents","volume":"935","author":"Deiana","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107690_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176821","article-title":"Investigating Cannabidiol\u2019s potential as a supplementary treatment for schizophrenia: a narrative review","volume":"979","author":"Denis V\u00f6lker","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2025.107690_bib40","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41573-023-00703-8","article-title":"Deuterium in drug discovery: progress, opportunities and challenges","volume":"22","author":"Di Martino","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib41","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1186\/s13063-023-07789-w","article-title":"Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial","volume":"24","author":"Dixon","year":"2023","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.phrs.2025.107690_bib42","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/schbul\/sbv065","article-title":"Targeting oxidative stress and aberrant critical period plasticity in the developmental trajectory to schizophrenia","volume":"41","author":"Do","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.phrs.2025.107690_bib43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/molpharm.121.000460","article-title":"Metabotropic glutamate receptors as emerging targets for the treatment of schizophrenia","volume":"101","author":"Dogra","year":"2022","journal-title":"Mol. Pharmacol."},{"issue":"8033","key":"10.1016\/j.phrs.2025.107690_bib44","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/d41586-024-03123-9","article-title":"Revolutionary drug for schizophrenia wins US approval","volume":"634","author":"Dolgin","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12888-014-0351-3","article-title":"A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia","volume":"14","author":"Downing","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jamapsychiatry.2013.2287","article-title":"In vivo evidence for cerebral bioenergetic abnormalities in schizophrenia measured using 31 P magnetization transfer spectroscopy","volume":"71","author":"Du","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.phrs.2025.107690_bib47","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/med.22042","article-title":"Beyond dopamine: novel strategies for schizophrenia treatment","volume":"44","author":"Dudzik","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2025.107690_bib48","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1523\/JNEUROSCI.0984-22.2022","article-title":"Lumateperone normalizes pathological levels of acute inflammation through important pathways known to be involved in mood regulation","volume":"43","author":"Dutheil","year":"2023","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2025.107690_bib49","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/schbul\/sbab066","article-title":"Timely N-acetyl-cysteine and environmental enrichment rescue oxidative stress-induced parvalbumin interneuron impairments via MMP9\/RAGE pathway: a translational approach for early intervention in psychosis","volume":"47","author":"Dwir","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107690_bib50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2024.07.025","article-title":"NMDAR dysfunction and the regulation of dopaminergic transmission in schizophrenia","volume":"271","author":"Dwyer","year":"2024","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.phrs.2025.107690_bib51","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tins.2015.06.002","article-title":"Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment","volume":"38","author":"Ellaithy","year":"2015","journal-title":"Trends Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2025.107690_bib52","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.neuron.2019.04.013","article-title":"Mitochondrial dysfunction leads to cortical under-connectivity and cognitive impairment","volume":"102","author":"Fernandez","year":"2019","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.phrs.2025.107690_bib53","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","article-title":"Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study","volume":"8","author":"Fleischhacker","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/j.phrs.2025.107690_bib54","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00406-018-0908-0","article-title":"Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort","volume":"269","author":"Fond","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2025.107690_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2024.01.002","article-title":"Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data","volume":"81","author":"Fountoulakis","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.phrs.2025.107690_bib56","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1007\/s11064-023-03956-2","article-title":"Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia","volume":"48","author":"Fradley","year":"2023","journal-title":"Neurochem. Res."},{"issue":"9","key":"10.1016\/j.phrs.2025.107690_bib57","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41380-024-02531-7","article-title":"Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor","volume":"29","author":"Gaitonde","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2025.107690_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.38","article-title":"Preventive effects of minocycline in a neurodevelopmental two-hit model with relevance to schizophrenia","volume":"6","author":"Giovanoli","year":"2016","journal-title":"Transl. Psychiatry"},{"issue":"6","key":"10.1016\/j.phrs.2025.107690_bib59","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/npp.2017.258","article-title":"A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia","volume":"43","author":"Girgis","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib60","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/schbul\/sbx199","article-title":"The circuitry of dopamine system regulation and its disruption in schizophrenia: insights into treatment and prevention","volume":"45","author":"Grace","year":"2019","journal-title":"Schizophr. Bull."},{"issue":"9","key":"10.1016\/j.phrs.2025.107690_bib61","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/mp.2010.88","article-title":"Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis","volume":"16","author":"Green","year":"2011","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tins.2022.10.010","article-title":"Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders","volume":"46","author":"Halff","year":"2023","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.phrs.2025.107690_bib63","author":"Roche","year":"2023","journal-title":"A Trial Effic. Saf. RO6889450 vs Place. Patients Acute Exacerbation Schizophr. Or. Schizoaffective Disord."},{"key":"10.1016\/j.phrs.2025.107690_bib64","author":"Roche","year":"2024","journal-title":"A Study Assess. Eff. RO6889450 (Ralmitaront) Particip. Schizophr. Or. Schizoaffective Disord. Negat. Symptoms"},{"issue":"8","key":"10.1016\/j.phrs.2025.107690_bib65","doi-asserted-by":"crossref","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment","volume":"69","author":"Howes","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2025.107690_bib66","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2025.107690_bib67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajmg.b.32766","article-title":"Genetic variability of serotonin pathway associated with schizophrenia onset, progression, and treatment","volume":"183","author":"Hrovatin","year":"2020","journal-title":"Am. J. Med. Genet. Part B: Neuropsychiatr. Genet."},{"key":"10.1016\/j.phrs.2025.107690_bib68","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbw088","article-title":"Microglia activation and schizophrenia: lessons from the effects of minocycline on postnatal neurogenesis, neuronal survival and synaptic pruning","author":"Inta","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107690_bib69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euroneuro.2024.07.005","article-title":"Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition","volume":"87","author":"James","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"10323","key":"10.1016\/j.phrs.2025.107690_bib70","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.phrs.2025.107690_bib71","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.mp.4001551","article-title":"Glutamate as a therapeutic target in psychiatric disorders","volume":"9","author":"Javitt","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107690_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1386263","article-title":"Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen","volume":"15","author":"Johnson","year":"2024","journal-title":"Front. Psychiatry"},{"issue":"10422","key":"10.1016\/j.phrs.2025.107690_bib73","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline\u2013trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.phrs.2025.107690_bib74","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41380-021-01313-9","article-title":"Mitochondrial, exosomal miR137-COX6A2 and gamma synchrony as biomarkers of parvalbumin interneurons, psychopathology, and neurocognition in schizophrenia","volume":"27","author":"Khadimallah","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.phrs.2025.107690_bib75","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia","volume":"78","author":"Kinon","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"16","key":"10.1016\/j.phrs.2025.107690_bib76","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A Non\u2013D2-receptor-binding drug for the treatment of schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107690_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.612471","article-title":"The role of peripheral inflammation in clinical outcome and brain imaging abnormalities in psychosis: a systematic review","volume":"12","author":"Kose","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"S1","key":"10.1016\/j.phrs.2025.107690_bib78","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib79","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41398-022-02253-w","article-title":"Glutamatergic dysfunction in Schizophrenia","volume":"12","author":"Kruse","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"10","key":"10.1016\/j.phrs.2025.107690_bib80","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.biopsych.2017.01.004","article-title":"Impaired tuning of neural ensembles and the pathophysiology of schizophrenia: a translational and computational neuroscience perspective","volume":"81","author":"Krystal","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"10369","key":"10.1016\/j.phrs.2025.107690_bib81","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","article-title":"Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial","volume":"400","author":"Krystal","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.phrs.2025.107690_bib82","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40263-022-00959-5","article-title":"Targeting d-amino acid oxidase (DAAO) for the treatment of schizophrenia: rationale and current status of research","volume":"36","author":"Kuo","year":"2022","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.phrs.2025.107690_bib83","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nn.3181","article-title":"HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity","volume":"15","author":"Kurita","year":"2012","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2025.107690_bib84","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1021\/acs.jmedchem.2c01521","article-title":"Discovery of MK-8189, a highly potent and selective PDE10A inhibitor for the treatment of schizophrenia","volume":"66","author":"Layton","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib85","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13063-019-3336-1","article-title":"Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)","volume":"20","author":"Lennox","year":"2019","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.phrs.2025.107690_bib86","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1176\/appi.ajp.20240738","article-title":"Antipsychotic drugs: a concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application","volume":"181","author":"Leucht","year":"2024","journal-title":"Am. J. Psychiatry"},{"issue":"02","key":"10.1016\/j.phrs.2025.107690_bib87","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","article-title":"A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia","volume":"71","author":"Levkovitz","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2025.107690_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2025.107690_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22225","article-title":"SEP-363856 exerts neuroprotection through the PI3K\/AKT\/GSK-3\u03b2 signaling pathway in a dual-hit neurodevelopmental model of schizophrenia-like mice","volume":"85","author":"Li","year":"2024","journal-title":"Drug Dev. Res."},{"issue":"8","key":"10.1016\/j.phrs.2025.107690_bib90","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.3390\/molecules27082550","article-title":"Effect of Co-treatment of olanzapine with SEP-363856 in mice models of schizophrenia","volume":"27","author":"Liang","year":"2022","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.phrs.2025.107690_bib91","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial","volume":"79","author":"Lieberman","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107690_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.11.008","article-title":"Repeated aripiprazole treatment regulates Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the rat brain","volume":"80","author":"Luoni","year":"2014","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.phrs.2025.107690_bib93","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1176\/ajp.2006.163.5.790","article-title":"Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis","volume":"163","author":"McGlashan","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"S1","key":"10.1016\/j.phrs.2025.107690_bib94","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1007\/BF00442563","article-title":"A prospective study of clozapine in treatment-resistant schizophrenic patients","volume":"99","author":"Meltzer","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2025.107690_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.600178","article-title":"PDE10A inhibitors\u2014clinical failure or window into antipsychotic drug action?","volume":"14","author":"Menniti","year":"2021","journal-title":"Front. Neurosci."},{"issue":"02","key":"10.1016\/j.phrs.2025.107690_bib96","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4088\/JCP.15l09920","article-title":"An open-label, pilot trial of adjunctive tocilizumab in schizophrenia","volume":"77","author":"Miller","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107690_bib97","author":"Neurosciences","year":"2019","journal-title":"Minerva Neurosci. Presents Pre-Clin. Data Suggest. a Mech. Role Roluperidone Address Negat. Symptoms Schizophr."},{"key":"10.1016\/j.phrs.2025.107690_bib98","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuropharm.2013.10.021","article-title":"Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action","volume":"79","author":"Mocci","year":"2014","journal-title":"Neuropharmacology"},{"issue":"5381","key":"10.1016\/j.phrs.2025.107690_bib99","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group ii metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib100","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107690_bib101","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.schres.2024.05.019","article-title":"Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: a randomized proof-of-concept clinical trial","volume":"270","author":"Mukai","year":"2024","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.phrs.2025.107690_bib102","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sby024","article-title":"Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations","volume":"44","author":"M\u00fcller","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib103","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41398-021-01607-0","article-title":"Neuroinflammation in schizophrenia: the role of nuclear factor kappa B","volume":"11","author":"Murphy","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107690_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107426","article-title":"The origin of NMDA receptor hypofunction in schizophrenia","volume":"205","author":"Nakazawa","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2025.107690_bib105","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"10074","key":"10.1016\/j.phrs.2025.107690_bib106","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet"},{"issue":"10039","key":"10.1016\/j.phrs.2025.107690_bib107","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.phrs.2025.107690_bib108","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2025.107690_bib109","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jpsychires.2023.01.042","article-title":"Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: a systematic review and meta-analysis","volume":"160","author":"Patlola","year":"2023","journal-title":"J. Psychiatr. Res."},{"issue":"8","key":"10.1016\/j.phrs.2025.107690_bib110","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.biopsych.2024.03.014","article-title":"Muscarinic Receptor Activators as Novel Treatments for Schizophrenia","volume":"96","author":"Paul","year":"2024","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2025.107690_bib111","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nn.2741","article-title":"Dendritic spine pathology in neuropsychiatric disorders","volume":"14","author":"Penzes","year":"2011","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib112","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41398-019-0603-6","article-title":"Region specific knockdown of Parvalbumin or Somatostatin produces neuronal and behavioral deficits consistent with those observed in schizophrenia","volume":"9","author":"Perez","year":"2019","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2025.107690_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg1679","article-title":"TrkB receptor interacts with mGlu 2 receptor and mediates antipsychotic-like effects of mGlu 2 receptor activation in the mouse","volume":"10","author":"Philibert","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2025.107690_bib114","author":"Pierre Fabre Medicament","year":"2016","journal-title":"F17464 Acute Schizophr. Trial (FAST)"},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2025.107690_bib116","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2023.03.028","article-title":"Long-term effects of Roluperidone on negative symptoms of schizophrenia","volume":"255","author":"Rabinowitz","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.phrs.2025.107690_bib117","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bbr.2017.02.036","article-title":"RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia","volume":"332","author":"Rajagopal","year":"2017","journal-title":"Behav. Brain Res."},{"issue":"11","key":"10.1016\/j.phrs.2025.107690_bib118","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/mp.2017.6","article-title":"Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242","volume":"22","author":"Ranganathan","year":"2017","journal-title":"Mol. Psychiatry"},{"issue":"9","key":"10.1016\/j.phrs.2025.107690_bib119","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.3390\/molecules27092755","article-title":"The POtential Antidepressant Action of Duloxetine Co-administered with the TAAR1 receptor agonist SEP-363856 in mice","volume":"27","author":"Ren","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2025.107690_bib120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euroneuro.2023.12.001","article-title":"The complex scenario behind the term antipsychotic drug","volume":"80","author":"Riva","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2025.107690_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104749","article-title":"Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors","volume":"156","author":"Rodrigues da Silva","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2025.107690_bib122","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/(SICI)1097-4547(20000415)60:2<202::AID-JNR9>3.0.CO;2-J","article-title":"N-methyl-D-aspartate (NMDA) receptors in the ventral tegmental area: Subcellular distribution and colocalization with 5-hydroxytryptamine2A receptors","volume":"60","author":"Rodr\u00edguez","year":"2000","journal-title":"J. Neurosci. Res."},{"issue":"9","key":"10.1016\/j.phrs.2025.107690_bib123","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/ijnp\/pyy062","article-title":"Kinetics of cytokine levels during antipsychotic treatment in schizophrenia: a meta-analysis","volume":"21","author":"Romeo","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107690_bib124","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cts.12578","article-title":"Evaluation of pharmacokinetics and pharmacodynamics of <scp>BI<\u202f\/scp>\u202f425809, a Novel GlyT1 inhibitor: translational studies","volume":"11","author":"Rosenbrock","year":"2018","journal-title":"Clin. Transl. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2025.107690_bib125","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.121.001071","article-title":"Effects of the glycine transporter-1 inhibitor iclepertin (BI 425809) on sensory processing, neural network function, and cognition in animal models related to schizophrenia","volume":"382","author":"Rosenbrock","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2025.107690_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109489","article-title":"The crosstalk between 5-HT2AR and mGluR2 in schizophrenia","volume":"230","author":"Saha","year":"2023","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib127","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41398-022-02254-9","article-title":"Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study","volume":"12","author":"Sauder","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"9","key":"10.1016\/j.phrs.2025.107690_bib128","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1176\/appi.ajp.2009.08091400","article-title":"Childhood motor coordination and adult schizophrenia spectrum disorders","volume":"166","author":"Schiffman","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2025.107690_bib129","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.biopsych.2024.08.019","article-title":"Finding the right dose: NMDA receptor\u2013modulating treatments for cognitive and plasticity deficits in schizophrenia and the role of pharmacodynamic target engagement","volume":"97","author":"Sehatpour","year":"2025","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.phrs.2025.107690_bib130","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jmedchem.5b00300","article-title":"The discovery and characterization of the \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N -{(3 S,4 S)-4-[4-(5-Cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242)","volume":"58","author":"Shaffer","year":"2015","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2025.107690_bib131","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective Muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2025.107690_bib132","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyae005","article-title":"Evenamide: a potential pharmacotherapeutic alternative for treatment-resistant schizophrenia","volume":"27","author":"Singh","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"7906","key":"10.1016\/j.phrs.2025.107690_bib133","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","article-title":"Rare coding variants in ten genes confer substantial risk for schizophrenia","volume":"604","author":"Singh","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107690_bib134","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-024-04474-0","article-title":"The Potential of Mitochondrial Therapeutics in the Treatment of Oxidative Stress and Inflammation in Aging","author":"Sinha","year":"2024","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107690_bib135","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-019-05387-w","article-title":"Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO","volume":"237","author":"Slifstein","year":"2020","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.phrs.2025.107690_bib136","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","article-title":"Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia","volume":"72","author":"Slifstein","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2025.107690_bib137","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.phrs.2025.107690_bib138","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1092852916000638","article-title":"Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia","volume":"22","author":"Solmi","year":"2017","journal-title":"CNS Spectr."},{"issue":"6","key":"10.1016\/j.phrs.2025.107690_bib139","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/schbul\/sbab047","article-title":"Peripubertal mGluR2\/3 agonist treatment prevents hippocampal dysfunction and dopamine system hyperactivity in adulthood in MAM model of schizophrenia","volume":"47","author":"Sonnenschein","year":"2021","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.phrs.2025.107690_bib140","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0022-3565(24)29291-0","article-title":"The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat","volume":"299","author":"Stanhope","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.phrs.2025.107690_bib141","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3390\/molecules23082087","article-title":"Current concepts and treatments of schizophrenia","volume":"23","author":"St\u0119pnicki","year":"2018","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib142","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2014.06.021","article-title":"Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a \u201ccentral hub\u201d in schizophrenia pathophysiology?","volume":"176","author":"Steullet","year":"2016","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.phrs.2025.107690_bib143","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/mp.2017.47","article-title":"Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia","volume":"22","author":"Steullet","year":"2017","journal-title":"Mol. Psychiatry"},{"issue":"9","key":"10.1016\/j.phrs.2025.107690_bib144","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41583-024-00837-7","article-title":"Schizophrenia genomics: genetic complexity and functional insights","volume":"25","author":"Sullivan","year":"2024","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2025.107690_bib145","author":"Sumitomo","year":"2023","journal-title":"Sumitomo Pharma Otsuka Announc. Topline Results Phase 3 Diam. 1 Diam. 2 Clin. Stud. Eval. Ulotaront Schizophr."},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib146","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1038\/s41598-019-40398-9","article-title":"Thalamic reticular nucleus parvalbumin neurons regulate sleep spindles and electrophysiological aspects of schizophrenia in mice","volume":"9","author":"Thankachan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2025.107690_bib147","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.euroneuro.2022.06.009","article-title":"Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: a dopamine D1 receptor dependent mechanism","volume":"62","author":"Titulaer","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7906","key":"10.1016\/j.phrs.2025.107690_bib148","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","article-title":"Mapping genomic loci implicates genes and synaptic biology in schizophrenia","volume":"604","author":"Trubetskoy","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107690_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116298","article-title":"The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia","volume":"228","author":"Uliana","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107690_bib150","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2025.107690_bib151","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2032-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2 R,3 R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2025.107690_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.727117","article-title":"Psychedelics and other psychoplastogens for treating mental illness","volume":"12","author":"Vargas","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"7","key":"10.1016\/j.phrs.2025.107690_bib153","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1038\/s41380-022-01572-0","article-title":"Dopaminergic dysfunction and excitatory\/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment","volume":"27","author":"Wada","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib154","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/schbul\/sbx035","article-title":"Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression","volume":"44","author":"Wang","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41380-022-01832-z","article-title":"Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation","volume":"28","author":"Wolf","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"16","key":"10.1016\/j.phrs.2025.107690_bib156","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1017\/S0033291724003088","article-title":"Brain structural damage networks at different stages of schizophrenia","volume":"54","author":"Xu","year":"2024","journal-title":"Psychol. Med."},{"issue":"7992","key":"10.1016\/j.phrs.2025.107690_bib157","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41586-023-06804-z","article-title":"Ligand recognition and G-protein coupling of trace amine receptor TAAR1","volume":"624","author":"Xu","year":"2023","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.phrs.2025.107690_bib158","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/s41380-018-0206-2","article-title":"Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators","volume":"25","author":"Yohn","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107690_bib159","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1421554","article-title":"The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia","volume":"15","author":"Yohn","year":"2024","journal-title":"Front. Psychiatry"},{"issue":"12","key":"10.1016\/j.phrs.2025.107690_bib160","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2025.107690_bib161","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41380-022-01718-0","article-title":"The neurobiology of duration of untreated psychosis: a comprehensive review","volume":"28","author":"Zoghbi","year":"2023","journal-title":"Mol. Psychiatry"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182500115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182500115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T02:19:43Z","timestamp":1742437183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182500115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":161,"alternative-id":["S104366182500115X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107690","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IUPHAR review \u2013 Novel therapeutic targets for schizophrenia treatment: A translational perspective","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107690"}}